Aim for lower LDL-C target?

The findings help answer the long-standing debate questioning the clinical benefit of further reducing LDL-C, said Professor Phil Aylward, an Australian investigator on the IMPROVE-IT trial and director of cardiac services at the Southern Adelaide Local Health Network.